Cargando…
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer
BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589984/ https://www.ncbi.nlm.nih.gov/pubmed/28772281 http://dx.doi.org/10.1038/bjc.2017.226 |
_version_ | 1783262447706046464 |
---|---|
author | Ciuleanu, Tudor-Eliade Ahmed, Samreen Kim, Joo-Hang Mezger, Jörg Park, Keunchil Thomas, Michael Chen, Jihong Poondru, Srinivasu VanTornout, Jan M Whitcomb, Debbie Blackhall, Fiona |
author_facet | Ciuleanu, Tudor-Eliade Ahmed, Samreen Kim, Joo-Hang Mezger, Jörg Park, Keunchil Thomas, Michael Chen, Jihong Poondru, Srinivasu VanTornout, Jan M Whitcomb, Debbie Blackhall, Fiona |
author_sort | Ciuleanu, Tudor-Eliade |
collection | PubMed |
description | BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade. This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC. METHODS: In this Phase II randomised trial, patients without progression following four cycles of first-line platinum-based chemotherapy (N=205) received continuous schedule maintenance oral linsitinib 150 mg or placebo BID combined with erlotinib 150 mg QD for 21-day cycles. The primary endpoint was progression-free survival (PFS). RESULTS: The study was unblinded early due to linsitinib non-superiority. No difference was found between the two treatment groups in median PFS of 125 days linsitinib vs 129 days placebo (P=0.601); no difference in overall survival (OS) was observed. Tolerability was similar, although in the linsitinib group, treatment-related adverse events and discontinuations were more frequent. No drug–drug interaction was implicated. CONCLUSIONS: Linsitinib maintenance therapy added to erlotinib did not improve PFS or OS in non-progressing NSCLC patients. This highlights the need for robust biomarkers of response for combinations that incorporate IGFR-targeted therapies in maintenance or other therapeutic settings. |
format | Online Article Text |
id | pubmed-5589984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55899842018-09-05 Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer Ciuleanu, Tudor-Eliade Ahmed, Samreen Kim, Joo-Hang Mezger, Jörg Park, Keunchil Thomas, Michael Chen, Jihong Poondru, Srinivasu VanTornout, Jan M Whitcomb, Debbie Blackhall, Fiona Br J Cancer Clinical Study BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade. This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC. METHODS: In this Phase II randomised trial, patients without progression following four cycles of first-line platinum-based chemotherapy (N=205) received continuous schedule maintenance oral linsitinib 150 mg or placebo BID combined with erlotinib 150 mg QD for 21-day cycles. The primary endpoint was progression-free survival (PFS). RESULTS: The study was unblinded early due to linsitinib non-superiority. No difference was found between the two treatment groups in median PFS of 125 days linsitinib vs 129 days placebo (P=0.601); no difference in overall survival (OS) was observed. Tolerability was similar, although in the linsitinib group, treatment-related adverse events and discontinuations were more frequent. No drug–drug interaction was implicated. CONCLUSIONS: Linsitinib maintenance therapy added to erlotinib did not improve PFS or OS in non-progressing NSCLC patients. This highlights the need for robust biomarkers of response for combinations that incorporate IGFR-targeted therapies in maintenance or other therapeutic settings. Nature Publishing Group 2017-09-05 2017-08-03 /pmc/articles/PMC5589984/ /pubmed/28772281 http://dx.doi.org/10.1038/bjc.2017.226 Text en Copyright © 2017 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Clinical Study Ciuleanu, Tudor-Eliade Ahmed, Samreen Kim, Joo-Hang Mezger, Jörg Park, Keunchil Thomas, Michael Chen, Jihong Poondru, Srinivasu VanTornout, Jan M Whitcomb, Debbie Blackhall, Fiona Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title_full | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title_fullStr | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title_full_unstemmed | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title_short | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
title_sort | randomised phase 2 study of maintenance linsitinib (osi-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589984/ https://www.ncbi.nlm.nih.gov/pubmed/28772281 http://dx.doi.org/10.1038/bjc.2017.226 |
work_keys_str_mv | AT ciuleanutudoreliade randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT ahmedsamreen randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT kimjoohang randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT mezgerjorg randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT parkkeunchil randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT thomasmichael randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT chenjihong randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT poondrusrinivasu randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT vantornoutjanm randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT whitcombdebbie randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer AT blackhallfiona randomisedphase2studyofmaintenancelinsitinibosi906incombinationwitherlotinibcomparedwithplacebopluserlotinibafterplatinumbasedchemotherapyinpatientswithadvancednonsmallcelllungcancer |